Drug Type Biosimilar, Monoclonal antibody |
Synonyms Arvestin, Bevacizumab Biosimilar (Aryogen Pharmed), Stivant + [2] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | IR | 04 Oct 2016 | |
Colorectal Cancer | Phase 3 | - | - |